RECRUITING

DESIFOR-EXPAND (MHIF)

Description

The DESIFOR pilot study was conducted to determine the feasibility of utilizing an n-of-1 trial to facilitate tolerance of unblinded rosuvastatin in patients with prior statin intolerance

Conditions

Statin TherapyStatin Adverse ReactionStatin
Talk to us

Related Conditions:

Statin TherapyStatin Adverse ReactionStatin

Study Overview

On this page

Study Details

Study overview

The DESIFOR pilot study was conducted to determine the feasibility of utilizing an n-of-1 trial to facilitate tolerance of unblinded rosuvastatin in patients with prior statin intolerance

The DEterminig Statin Intolerance for Rosuvastatin Trial

DESIFOR-EXPAND (MHIF)

Condition
Statin Therapy
Intervention / Treatment

-

Contacts and Locations

Minneapolis

Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States, 55407

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult patients (≥ 21 years old) with a prior history of statin intolerance. Statin intolerance is defined by discontinuation of at least 2 different statin medications due to possible side effects. Patients can participate in the trial while on other lipid-lowering agents, such as ezetimibe and PSCK9 inhibitors, as long as the patient has been on the other lipid lowering therapy and tolerating it well for at least 1 month. For individuals with established ASCVD or multiple ASCVD risk factors, initiation of other lipid lowering therapy prior to participation in DESIFOR is encouraged.
  • * 2. At least 30 days since discontinued use of a statin
  • * Women who are pregnant, nursing or attempting to become pregnant
  • * Individuals who experienced severe reactions in the past, including rhabdomyolysis, severe myositis, anaphylaxis
  • * Individuals who are not otherwise clinically indicated to take rosuvastatin 20 mg

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Minneapolis Heart Institute Foundation,

Study Record Dates

2026-12-31